Moleculera Biosciences Revenue and Competitors
Estimated Revenue & Valuation
- Moleculera Biosciences's estimated annual revenue is currently $2.5M per year.
- Moleculera Biosciences's estimated revenue per employee is $155,000
- Moleculera Biosciences's total funding is $6M.
Employee Data
- Moleculera Biosciences has 16 Employees.
- Moleculera Biosciences grew their employee count by -6% last year.
Moleculera Biosciences's People
| Name | Title | Email/Phone |
|---|---|---|
1 | President & CEO | Reveal Email/Phone |
2 | Co-Founder, President and CEO | Reveal Email/Phone |
3 | Chief Financial Officer | Reveal Email/Phone |
4 | Billing Manager/Administrative Coordinator | Reveal Email/Phone |
Moleculera Biosciences Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $1.6M | 10 | 67% | N/A | N/A |
#2 | $0.9M | 6 | 0% | N/A | N/A |
#3 | $21.2M | 137 | 3% | N/A | N/A |
#4 | $0.8M | 5 | 0% | N/A | N/A |
#5 | $79.6M | 367 | -3% | $42.5M | N/A |
#6 | $2.6M | 17 | -6% | N/A | N/A |
#7 | $1.6M | 10 | 11% | N/A | N/A |
#8 | $2.5M | 16 | -6% | $5.89M | N/A |
#9 | $0.9M | 6 | 0% | N/A | N/A |
#10 | $4.8M | 31 | -3% | N/A | N/A |
What Is Moleculera Biosciences?
Moleculera Biosciences is a precision medicine company focused on identifying and directing treatment for immune-mediated causes of chronic debilitating disorders. Through our fully-accredited CLIA/COLA clinical laboratory, we specialize in molecular diagnostic testing for autoimmune neuroimmunology. As pioneers focusing on neuropsychiatric disorders caused by molecular mimicry, we offer the Autoimmune Brain Panel™, an aid to a physician’s diagnosis of autoimmune-based neuropsychiatric disorders.\n\nThe Autoimmune Brain Panel™ helps identify whether an individual’s neurologic/psychiatric symptoms, such as obsessive compulsive behaviors, tics, anxiety, attention deficit hyperactivity disorder, and sometimes behaviors associated with Autism Spectrum Disorders, could be caused by a treatable autoimmune condition triggered by common infections.
keywords:N/A
$6M
Total Funding
16
Number of Employees
$2.5M
Revenue (est)
-6%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in Oklahoma City
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $2.4M | 16 | -20% | N/A |
#2 | $2.2M | 16 | 45% | N/A |
#3 | $1M | 16 | 0% | N/A |
#4 | $2.6M | 16 | 7% | N/A |
#5 | $1.4M | 16 | 7% | N/A |